Monitor the upcoming data presentations in November (velinotamig at ACR) and December (CLN-978 and CLN-049) for proof-of-concept and safety signals that could drive significant stock movement. The FDA meeting success for CLN-049 adds optionality but requires positive Phase 1 data to materialize.
Price Chart
Executive Summary
Cullinan Therapeutics outlined Q4 2026 milestones across its T cell engager pipeline, including multi-dose data for CLN-978 (CD19 TCE) in SLE, RA, and Sjögren's disease in December; velinotamig (BCMA TCE) data in SLE at ACR Convergence in November; and updated CLN-049 (FLT3 TCE) data in AML in December. The press release also notes a recent successful FDA meeting supporting a potentially registrational Phase 2 study for CLN-049. This is a forward-looking pipeline update with no financial data, making it a neutral catalyst event with moderate impact as the upcoming data readouts represent key de-risking milestones.
Key Facts
- CLN-978 multi-dose and single target dose regimen data in SLE, RA, and Sjögren's disease expected in December 2026.
- Velinotamig multi-dose regimen data in SLE to be presented at ACR Convergence 2026 on November 8, 2026.
- CLN-049 updated Phase 1 dose escalation data in relapsed/refractory AML expected in December 2026.
- Company notes a recent successful FDA meeting supporting initiation of a potentially registrational Phase 2 study for CLN-049.
- No financial data, revenue, or earnings figures were disclosed in the filing.
Financial Impact
No financial figures disclosed; impact depends on clinical data outcomes.
Risk Factors
- Clinical data may fail to meet efficacy or safety expectations, leading to negative stock reaction.
- Forward-looking statements are subject to clinical trial risks and regulatory uncertainties.
- No financial data provided; the filing is purely a pipeline update with no near-term revenue catalyst.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-400144 |
| Document: cgem-ex99_1.htm | 0001193125-26-400144 |
| Document: 0001193125-26-400144-index-headers.html | 0001193125-26-400144 |
| Document: 0001193125-26-400144-index.html | 0001193125-26-400144 |
| Document: 0001193125-26-400144.txt | 0001193125-26-400144 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | Press Release | $15.51 | awaiting T+60 | — | $14.53 (−6.32%) |
Sep 24, 2026 4w ago | 8-K | $15.44 | awaiting T+60 | — | $14.53 (−5.89%) |
Sep 24, 2026 4w ago | Press Release | $15.44 | awaiting T+60 | — | $14.53 (−5.89%) |
Sep 22, 2026 4w ago | Institutional Cluster | $21.67 | awaiting T+60 | — | $14.53 (−32.95%) |
Sep 14, 2026 6w ago | 8-K | $20.40 | awaiting T+60 | — | $14.53 (−28.77%) |
Aug 6, 2026 11w ago | 8-K | $17.95 | awaiting T+60 | — | $14.53 (−19.05%) |
Jun 11, 2026 19w ago | Institutional Cluster | $12.98 $21.69 | ▲ +67.10% | ▲ +63.28% | $14.53 (+11.94%) |
Jun 10, 2026 19w ago | Press Release | $12.05 $22.09 | ▲ +83.32% | ▲ +77.15% | $14.53 (+20.58%) |
Jun 8, 2026 20w ago | 8-K | $13.28 $22.33 | ▲ +68.15% | ▲ +64.64% | $14.53 (+9.41%) |
May 19, 2026 22w ago | Press Release | $14.18 $19.64 | ▲ +38.55% | ▲ +32.26% | $14.53 (+2.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers